JP2009533475A5 - - Google Patents

Info

Publication number

JP2009533475A5

JP2009533475A5 JP2009505636A JP2009505636A JP2009533475A5 JP 2009533475 A5 JP2009533475 A5 JP 2009533475A5 JP 2009505636 A JP2009505636 A JP 2009505636A JP 2009505636 A JP2009505636 A JP 2009505636A JP 2009533475 A5 JP2009533475 A5 JP 2009533475A5

Authority

JP

Japan

Prior art keywords

composition

nucleotides

seq

interfering rna

mrna

Prior art date

2007-04-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002773 nucleotide Substances 0.000 claims description 117
• 125000003729 nucleotide group Chemical group 0.000 claims description 117
• 239000000203 mixture Substances 0.000 claims description 80
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 78
• 230000002452 interceptive effect Effects 0.000 claims description 78
• 108020004999 messenger RNA Proteins 0.000 claims description 63
• 101150110875 Syk gene Proteins 0.000 claims description 46
• 230000004968 inflammatory condition Effects 0.000 claims description 29
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
• 108020004459 Small interfering RNA Proteins 0.000 claims description 20
• 230000000692 anti-sense effect Effects 0.000 claims description 20
• 108091081021 Sense strand Proteins 0.000 claims description 12
• 239000000443 aerosol Substances 0.000 claims description 12
• 210000004207 dermis Anatomy 0.000 claims description 12
• 239000013604 expression vector Substances 0.000 claims description 12
• 238000001727 in vivo Methods 0.000 claims description 12
• 238000007918 intramuscular administration Methods 0.000 claims description 12
• 238000007912 intraperitoneal administration Methods 0.000 claims description 12
• 238000001990 intravenous administration Methods 0.000 claims description 12
• 108091070501 miRNA Proteins 0.000 claims description 12
• 239000002679 microRNA Substances 0.000 claims description 12
• 239000002924 silencing RNA Substances 0.000 claims description 12
• 238000007920 subcutaneous administration Methods 0.000 claims description 12
• 230000000699 topical effect Effects 0.000 claims description 12
• 230000000295 complement effect Effects 0.000 claims description 10
• 230000004962 physiological condition Effects 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 9
• 108091027967 Small hairpin RNA Proteins 0.000 claims description 8
• 239000004055 small Interfering RNA Substances 0.000 claims description 8
• 206010010741 Conjunctivitis Diseases 0.000 claims description 4
• 206010061218 Inflammation Diseases 0.000 claims description 4
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 4
• 230000009368 gene silencing by RNA Effects 0.000 claims description 4
• 230000004054 inflammatory process Effects 0.000 claims description 4
• 230000007423 decrease Effects 0.000 claims description 3
• 230000003247 decreasing effect Effects 0.000 claims description 2
• 239000004615 ingredient Substances 0.000 claims 2
• 238000000034 method Methods 0.000 description 44
• 206010015943 Eye inflammation Diseases 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 239000003814 drug Substances 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1